ACMELAB: Declaration of share transfer by a Sponsor16 Mar 2026
Ms. Parveen Akhter Khanam, Sponsor of the company, has expressed her intention to transfer 740,000 shares of the company to her son Mr. Ansar Uddin Sinha (General Shareholder of the company), by way of gift outside the trading system of the Exchange within thirty working days with effect from March 15, 2026.
ACMELAB: Q2 Financials29 Jan 2026
(Q2 Un-audited): EPS was Tk. 3.10 for October-December 2025 as against Tk. 2.86 for October-December 2024; EPS was Tk. 6.11 for July-December 2025 as against Tk. 5.47 for July-December 2024. NOCFPS was Tk. 12.16 for July-December 2025 as against Tk. 6.85 (Restated) for July-December 2024. NAV per share was Tk. 128.97 as on December 31, 2025 and Tk. 126.37 as on June 30, 2025.
ACMELAB: Board Meeting schedule under LR 16(1)25 Jan 2026
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2026 at 3:45 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
ACMELAB: Dividend Disbursement21 Jan 2026
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
ACMELAB: Credit Rating Result11 Dec 2025
Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AA" in the long term and "ST-2" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2025 also unaudited financials up to September 30, 2025 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
ACMELAB: Resumption after Record Date18 Nov 2025
Trading of the shares of the company will resume on 19.11.2025.
ACMELAB: Suspension for Record Date17 Nov 2025
Trading of the shares of the company will remain suspended on record date i.e., 18.11.2025.
ACMELAB: Q1 Financials13 Nov 2025
(Q1 Un-audited): EPS was Tk. 3.01 for July-September 2025 as against Tk. 2.61 for July-September 2024; NOCFPS was Tk. 7.07 for July-September 2025 as against Tk. 6.44 for July-September 2024. NAV per share was Tk. 129.38 as on September 30, 2025 and Tk. 126.37 as on June 30, 2025.
ACMELAB: Spot News13 Nov 2025
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 16.11.2025 to 17.11.2025 and trading of the shares will remain suspended on record date i.e., 18.11.2025.
ACMELAB: Board Meeting schedule under LR 16(1)06 Nov 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
ACMELAB: Dividend Declaration28 Oct 2025
The Board of Directors has recommended 35% Cash Dividend for the year ended June 30, 2025. Date of AGM: 22.12.2025, Time: 11:30 AM, Venue: Digital Platform. Record Date: 18.11.2025. The Company has also reported EPS of Tk. 11.48, NAV per share of Tk. 126.37 and NOCFPS of Tk. 15.04 for the year ended June 30, 2025 as against Tk. 11.61, Tk. 118.39 and Tk. 9.24 respectively for the year ended June 30, 2024.
ACMELAB: Price Limit Open28 Oct 2025
There will be no price limit on the trading of the shares of the Company today (28.10.2025) following its corporate declaration.
ACMELAB: Board Meeting schedule under LR 19(1)19 Oct 2025
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2025 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
ACMELAB: Q3 Financials29 Apr 2025
(Q3 Un-audited): EPS was Tk. 2.81 for January-March 2025 as against Tk. 2.75 for January-March 2024; EPS was Tk. 8.28 for July 2024-March 2025 as against Tk. 8.53 for July 2023-March 2024. NOCFPS was Tk. 7.79 for July 2024-March 2025 as against Tk. 5.77 for July 2023-March 2024. NAV per share was Tk. 123.18 as on March 31, 2025 and Tk. 118.39 as on June 30, 2024.
ACMELAB: Board Meeting schedule under LR 16(1)22 Apr 2025
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.